Skip to content

Trial · Interventional

CompletedPhase 3Registry data

Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

NCTNCT07834398 (opens ClinicalTrials.gov in a new tab)Other idKACST,KSA:H-11-N-140
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 3
Enrollment
150 participants (actual)
Sponsor
Zagazig University · Other gov
Design
Randomized · Open label (no masking)
Countries
1 country

Saudi Arabia

Start
14 Nov 2025
Primary completion
13 Apr 2026
Completion
21 Apr 2026
First posted
22 Sept 2026
Last update posted
22 Sept 2026
Conditions
Non-diabetec Obesity · Obesity (Disorder)

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202520262027
  1. Ph 3

    Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

    NCT07834398

    14 Nov 2025 to 21 Apr 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI \>30 will be randomized into three groups and followed for 6 months to assess changes in weight, BMI, lipid profile, and liver functions.

Interventions

  • DulaglutideDrug
  • SemagludtideDrug
  • TirzepatideDrug

Arms3

  • Active comparator

    Dulaglutide Group

    Includes 50 non-diabetic obese participants receiving dulaglutide 1.5 mg subcutaneous once weekly for 24 weeks

  • Active comparator

    Semaglutide Group

    Includes 50 non-diabetic obese participants receiving semaglutide 2.4 mg subcutaneous once weekly for 24 weeks

  • Active comparator

    Tirzepatide Group

    Includes 50 non-diabetic obese participants receiving Tirzepatide 15 mg subcutaneous once weekly for 24 weeks

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. change in body weight at 3 and 6 months

    Time frame · Baseline, Week 12 (3 months) and Week 24 (6 months)

    Registry description

    Change from baseline in body weight (kg) at 3 and 6 months analyzed separately among obese non-diabetic participants receiving weekly GLP-1 receptor agonists.

Secondary outcomes(8)

  1. Change in Body Mass Index (BMI)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in BMI from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: kg/m²

  2. Change in Glycated Hemoglobin (HbA1c)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in HbA1c from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: %

  3. Change in Low-Density Lipoprotein Cholesterol (LDL-C)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in LDL-C from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: mg/dL

  4. Change in Triglycerides

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in serum triglyceride concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: mg/dL

  5. Change in High-Density Lipoprotein Cholesterol (HDL-C)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in HDL-C from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: mg/dL

  6. Change in Total Cholesterol (TC)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in TC from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: mg/dL

  7. Change in Alanine Aminotransferase (ALT)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in serum ALT concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: U/L

  8. Change in Aspartate Aminotransferase (AST)

    Time frame · Baseline, 3 months, and 6 months]

    Registry description

    Change in serum AST concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in obese non-diabetic participants. Unit of Measure: U/L

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 65 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Subjects (above 18 years old) obese body mass index (BMI) above 30 Exclusion Criteria: * Subjects with liver disease, renal dysfunction diabetes, pancreatic diseases ,thyroid disorder or goiter psychological diseases like depression and pregnant women, and Patients who will refuse

PepBank is a research reference. Talk to a doctor before you use any peptide.